Known targets — ChEMBL curated mechanism
FLT1FLT3FLT4KDRKITMETPDGFRAPDGFRBTEK
The experimentally established mechanism targets of Foretinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 16/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 5/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 1.00 |
| ▸ | TEK known ✓ | Q02763 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 3/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 1.00 |
| ▸ | MUSK | O15146 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | MAP3K13 | O43283 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372153 | 1.00 | MET (1.00) | METKDRFLT3AXLRET | |
| SCHEMBL29693444 | 1.00 | MET (1.00) | METKDRFLT3AXLRET | |
| Foretinib SCHEMBL30498609 | 1.00 | MET (1.00) | METKDRFLT3AXLRET | |
| Foretinib SCHEMBL29358674 | 1.00 | MET (1.00) | METKDRFLT3AXLRET | |
| Foretinib SCHEMBL2452880 | 0.99 | MET (0.99) | METKDRFLT3AXLRET | |
| Foretinib SCHEMBL958129 | 0.97 | MET (0.95) | METKDRFLT3AXLRET | |
| SCHEMBL14742522 | 0.95 | MET (0.91) | METKDRFLT3AXLRET | |
| SCHEMBL15003127 | 0.95 | MET (0.91) | METKDRFLT3AXLRET | |
| SCHEMBL19370040 | 0.95 | MET (0.91) | METKDRFLT3AXLRET | |
| SCHEMBL16070054 | 0.94 | MET (0.90) | METKDRFLT3AXLRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3272 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| CN-122005807-A | Application of HGF receptor inhibitor in preparation of medicine for treating/preventing myasthenia gravis | 重庆医科大学附属第一医院 | 2026-05-12 | — | — | CN | claimed |
| EP-4735002-A1 | TREATMENT METHODS FOR SUBJECTS WITH NON-SMALL CELL LUNG CANCER HAVING AN ABERRATION IN EGFR | Taiho Pharmaceutical Co., Ltd. (JP) | 2026-05-06 | — | — | EP | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-4719387-A2 | COMPLEMENT ANTIBODY-DRUG CONJUGATES | ADS Therapeutics LLC (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4712963-A2 | SMALL MOLECULE INHIBITORS OF P27 | Concarlo Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260069610-A1 | INHIBITION OF EFFEROCYTOSIS AS A TREATMENT TO PREVENT BONE LOSS AND INCREASE BONE DENSITY AND STRENGTH | UNIVERSITY OF ROCHESTER (US) | 2026-03-12 | — | — | US | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260021106-A1 | COMBINATION THERAPY FOR TREATING CANCERS | GEISTLICH PHARMA AG (CH) | 2026-01-22 | — | — | US | claimed |
| EP-4680251-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Thomas Jefferson University (US) | 2026-01-21 | — | — | EP | claimed |
| US-20130143881-A1 | Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-20120270872-A1 | Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2012-10-25 | — | — | US | claimed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | claimed |
| EP-2454238-A1 | CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUINOLIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE | Exelixis, Inc. (US) | 2012-05-23 | — | — | EP | claimed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | claimed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | claimed |
| WO-2011009095-A1 | CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUIN0LIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2011-01-20 | — | — | WO | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | claimed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | claimed |